Professor & patients' paper on the solvable biological challenge of ME/CFS: reader-friendly version
Simon McGrath provides a patient-friendly version of a peer-reviewed paper which highlights some of the most promising biomedical research on ME/CFS ...
Discuss the article on the Forums.

Blisibimod for B-Cell Mediated Autoimmune Disease

Discussion in 'Other Health News and Research' started by merylg, Dec 4, 2011.

  1. merylg

    merylg Senior Member

    Messages:
    802
    Likes:
    585
    Sydney, NSW, Australia
    http://www.bioportfolio.com/news/ar...nterim-B-cell-Analysis-Of-Pearl-sc-Study.html

    "About B-Cell Activating Factor (BAFF) and blisibimod

    BAFF has been associated with a wide range of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications."
     

See more popular forum discussions.

Share This Page